Your browser doesn't support javascript.
loading
The T-Cell Growth Factor Interleukin-2, Which Is Occasionally Targeted by Autoantibodies, Qualifies as Drug for the Treatment of Allergy, Autoimmunity, and Cancer: Collegium Internationale Allergologicum (CIA) Update 2024.
Sehgal, Al Nasar Ahmed; Tauber, Peter A; Stieger, Robert B; Kratzer, Bernhard; Pickl, Winfried F.
Afiliación
  • Sehgal ANA; Center for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, Wien, Austria.
  • Tauber PA; Center for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, Wien, Austria.
  • Stieger RB; Center for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, Wien, Austria.
  • Kratzer B; Center for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, Wien, Austria.
  • Pickl WF; Center for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, Wien, Austria.
Int Arch Allergy Immunol ; 185(3): 286-300, 2024.
Article en En | MEDLINE | ID: mdl-38086339
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hipersensibilidad / Neoplasias Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hipersensibilidad / Neoplasias Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article